KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

AbCellera Biologics (ABCL) EBIAT (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed EBIAT for 4 consecutive years, with -$47.2 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBIAT fell 57.73% year-over-year to -$47.2 million, compared with a TTM value of -$146.4 million through Dec 2023, down 192.35%, and an annual FY2024 reading of -$162.9 million, down 11.24% over the prior year.
  • EBIAT was -$47.2 million for Q4 2023 at AbCellera Biologics, down from -$28.6 million in the prior quarter.
  • Across five years, EBIAT topped out at $168.6 million in Q1 2022 and bottomed at -$47.2 million in Q4 2023.
  • Average EBIAT over 4 years is $17.8 million, with a median of -$2.5 million recorded in 2020.
  • Peak annual rise in EBIAT hit 5700.62% in 2021, while the deepest fall reached 693.91% in 2021.
  • Year by year, EBIAT stood at $117.0 million in 2020, then tumbled by 48.76% to $59.9 million in 2021, then plummeted by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.2 million in 2023.
  • Business Quant data shows EBIAT for ABCL at -$47.2 million in Q4 2023, -$28.6 million in Q3 2023, and -$30.5 million in Q2 2023.